Also indexed as: Acetylcarnitine, ALC, L-Acetyl-Carnitine
What does it do? Acetyl-L-carnitine is similar in form to the
amino acid L-carnitine and also has some similar
functions, such as being involved in the metabolism of food into energy.
The acetyl group that is part of acetyl-L-carnitine contributes to the production of the
neurotransmitter acetylcholine, which is required for mental function. Several double-blind
clinical trials suggest that acetyl-L-carnitine delays the progression of Alzheimer’s disease 1 2 and
enhances overall performance in some people with Alzheimer’s disease.3
Alzheimer’s research has been done with the acetyl-L-carnitine form, rather than the
L-carnitine form, of this nutrient.
One double-blind trial4 has found that acetyl-L-carnitine may be helpful for
people with degenerative cerebellar ataxia, a loss of muscular coordination caused by disease
in the cerebellum (the hind part of the brain that controls muscle tone and balance).
Where is it found? Acetyl-L-carnitine is a molecule that
occurs naturally in the brain, liver, and kidney. It is also available as a dietary
supplement.
Acetyl-L-carnitine has
been used in connection with the following conditions (refer to the
individual health concern for complete information):
Who is likely to be deficient? Acetyl-L-carnitine levels may
decrease with advancing age. However, because it is not an essential nutrient, true
deficiencies do not occur.
How much is usually taken? Most research involving
acetyl-L-carnitine has used 500 mg three times per day, though some research has used double
this amount.5
Are there any side effects or interactions? Side effects from
taking acetyl-L-carnitine are uncommon, although skin rash, increased appetite, nausea,
vomiting, agitation, and body odor have been reported in people taking
acetyl-L-carnitine.6 7
Are there any drug interactions? Certain medications may
interact with acetyl-L-carnitine. Refer to the drug interactions safety check for a list of those
medications.
References:
1. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and
neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol
Aging 1995;16:1–4.
2. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot
study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol
1992;49:1137–41.
3. Cucinotta D, Passeri M, Ventura S, et al. Multicenter clinical
placebo-controlled study with acetyl-L-carnitine (LAC) in the treatment of mildly demented
elderly patients. Drug Development Res 1988;14:213–6.
4. Sorbi S, Forleo P, Fani C, Piacentini S. Double-blind, crossover,
placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative
cerebellar ataxia. Clin Neuropharmacol 2000;23:114–8.
5. No authors listed. Acetyl-L-Carnitine. Altern Med Rev
1999;4:438–41 [review].
6. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter
placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease.
Neurology 1996;47:705–11.
7. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled
study of acetyl-L-carnitine in patients with Alzheimer’s dementia. Curr Med Res
Opin 1990;11:638–47.
Copyright © 2002 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.
|